Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARCH CAPITAL GROUP LTD.ACGL · Entity 3120 | Director | June 03, 2026 | June 04, 2026 |
| Dyne Therapeutics, Inc.DYN · Entity 3948 | Director | October 02, 2026 | October 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARCH CAPITAL GROUP LTD.
Report date June 03, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Depositary Shares, Series FSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-06-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-03 · Sale · Disposed 3,000 · Balance 0 F1: Each Depositary Share Represents 1/1,000th interest in a Series F Non-Cumulative Preferred Share. F2: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $19.57 to $19.80. Upon request, the full information regarding the number of shares sold at each separate price within the range will be provided to the issuer, any security holder of the issuer or the staff of the Securities Exchange Commission. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Depositary Share Represents 1/1,000th interest in a Series F Non-Cumulative Preferred Share.
F2: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $19.57 to $19.80. Upon request, the full information regarding the number of shares sold at each separate price within the range will be provided to the issuer, any security holder of the issuer or the staff of the Securities Exchange Commission.
Dyne Therapeutics, Inc.
Report date October 02, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,000 |
Reported balance
After 2026-10-02 transaction · row 1
1 source rowRow 1 · 2026-10-02 · Purchase · Acquired 2,500 · Balance 27,000 |
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOGEN INC.
Report date December 31, 2022 · Filed January 27, 2023
Section 16 reporting ended · disclosed 2023-01-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,025 |
Reported balance
After 2022-06-07 transaction · row 1
1 source rowRow 1 · 2022-06-07 · Gift · Disposed 150 · Balance 8,025 |
Bioverativ Inc.
Report date March 08, 2018 · Filed March 08, 2018
Section 16 reporting ended · disclosed 2018-03-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-03-08 transaction · row 1
1 source rowRow 1 · 2018-03-08 · Disposition to issuer · Disposed 6,693 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the "Merger Agreement"), between the Company, Sanofi, a French soci?t? anonyme (the "Parent"), and Blink Acquisition Corp. ("Merger Sub"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $105.00 in cash. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-03-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-03-08 · Disposition to issuer · Disposed 6,364 · Balance 0 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one Share of the issuer's common stock. F3: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $44.51 | Direct | 0 |
Reported balance
After 2018-03-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-03-08 · Disposition to issuer · Disposed 2,980 · Balance 0 F4: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $44.51 | Direct | 0 |
Reported balance
After 2018-03-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-03-08 · Disposition to issuer · Disposed 26,818 · Balance 0 F4: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the "Merger Agreement"), between the Company, Sanofi, a French soci?t? anonyme (the "Parent"), and Blink Acquisition Corp. ("Merger Sub"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $105.00 in cash.
F2: Each restricted stock unit ("RSU") represents a contingent right to receive one Share of the issuer's common stock.
F3: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes.
F4: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 02, 2026 Filed Oct 6, 2026 20:15 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | PurchaseCommon Stock | 2,500 | $16.00 | $40,000.00 |
DisclosureSEC source: 0001193125-26-415584 · ownership.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Read SEC document |
| June 08, 2026 Filed Jun 9, 2026 21:06 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | PurchaseCommon Stock | 2,000 | $16.94 | $33,880.00 |
DisclosureSEC source: 0001193125-26-264004 · ownership.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,500 Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 21:06 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock option (right to buy) · Derivative | 35,152 | $0.00 Strike: $17.04 | $0.00 |
DisclosureSEC source: 0001193125-26-264004 · ownership.xml · derivative · entry 2 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,152 Underlying: Common Stock · 35,152 shares Expires 2036-06-04 F1 · derivative.exercise_date: This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service. Read SEC document |
| June 03, 2026 Filed Jun 4, 2026 22:23 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | SaleDepositary Shares, Series F | 3,000 | $19.66 | $58,980.00 |
DisclosureSEC source: 0001372455-26-000008 · wk-form4_1780611787.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · security: Each Depositary Share Represents 1/1,000th interest in a Series F Non-Cumulative Preferred Share. F2 · price: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $19.57 to $19.80. Upon request, the full information regarding the number of shares sold at each separate price within the range will be provided to the issuer, any security holder of the issuer or the staff of the Securities Exchange Commission. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:10 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | PurchaseCommon Stock | 2,500 | $17.48 | $43,700.00 |
DisclosureSEC source: 0001193125-26-259563 · ownership.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:11 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | PurchaseCommon Stock | 2,000 | $18.21 | $36,420.00 |
DisclosureSEC source: 0001193125-26-245237 · ownership.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:10 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | PurchaseCommon Stock | 2,500 | $17.12 | $42,800.00 |
DisclosureSEC source: 0001193125-26-236877 · ownership.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Read SEC document |
| May 11, 2026 Filed May 12, 2026 20:32 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | SaleDepositary Shares, Series G | 2,000 | $17.14 | $34,283.00 |
DisclosureSEC source: 0001372455-26-000006 · wk-form4_1778617947.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · security: Each Depositary Share Represents 1/1,000th interest in a Series G Non-Cumulative Preferred Share. F2 · price: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $17.14 to $17.17. Upon request, the full information regarding the number of shares sold at each separate price within the range will be provided to the issuer, any security holder of the issuer or the staff of the Securities Exchange Commission. Read SEC document |
| May 05, 2026 Filed May 7, 2026 20:50 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | GrantCommon Shares, $.0011 par value per share | 2,071 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001372455-26-000004 · wk-form4_1778187003.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,175 F1 · price: Subject to the terms of the restricted share agreement, represents restricted shares that will become vested on the date that is the earlier of 1) one year following the grant date or 2) Arch Capital Group Ltd.'s next Annual General Meeting of Shareholders. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 20:27 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | PurchaseCommon Stock | 2,000 | $17.08 | $34,160.00 |
DisclosureSEC source: 0001193125-26-137998 · ownership.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,500 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices within the range of $17.06 to $17.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. Read SEC document |
| March 11, 2026 Filed Mar 12, 2026 20:29 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | SaleDepositary Shares, Series G | 3,000 | $17.12 | $51,345.00 |
DisclosureSEC source: 0001372455-26-000002 · wk-form4_1773347368.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 F1 · security: Each Depositary Share Represents 1/1,000th interest in a Series G Non-Cumulative Preferred Share. F2 · price: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $17.1149 to $17.1150. Upon request, the full information regarding the number of shares sold at each separate price within the range will be provided to the issuer, any security holder of the issuer or the staff of the Securities Exchange Commission. Read SEC document |
| March 11, 2026 Filed Mar 13, 2026 20:46 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | PurchaseCommon Stock | 2,000 | $19.35 | $38,700.00 |
DisclosureSEC source: 0001193125-26-106306 · ownership.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,500 Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 21:33 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | PurchaseCommon Stock | 3,000 | $15.06 | $45,180.00 |
DisclosureSEC source: 0001193125-26-100485 · ownership.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,500 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices within the range of $14.96 to $15.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. Read SEC document |
| October 01, 2025 Filed Oct 2, 2025 20:18 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock option (right to buy) · Derivative | 70,000 | $0.00 Strike: $12.50 | $0.00 |
DisclosureSEC source: 0001193125-25-228360 · ownership.xml · derivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2035-09-30 F1 · derivative.exercise_date: The option was granted on October 1, 2025. The shares underlying the option are scheduled to vest over three years in equal monthly installments through October 1, 2028. Read SEC document |
| August 01, 2025 Filed Aug 4, 2025 20:23 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | PurchaseDepositary Shares, Series G | 1,000 | $17.34 | $17,338.00 |
DisclosureSEC source: 0001415889-25-020959 · form4-08042025_080803.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 F1 · security: Each Depositary Share Represents 1/1,000th interest in a Series G Non-Cumulative Preferred Share. Read SEC document |
| May 07, 2025 Filed May 9, 2025 21:15 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | GrantCommon Shares, $.0011 par value per share | 1,564 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-012562 · form4-05092025_090529.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,104 F1 · price: Subject to the terms of the restricted share agreement, represents restricted shares that will become vested on the date that is the earlier of 1) one year following the grant date or 2) Arch Capital Group Ltd.'s next Annual General Meeting of Shareholders. Read SEC document |
| May 09, 2024 Filed May 13, 2024 22:51 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | GrantCommon Shares, $.0011 par value per share | 1,455 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-013065 · form4-05132024_100534.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,540 F1 · price: Subject to the terms of the restricted share agreement, represents restricted shares that will vest on May 9, 2025. Read SEC document |
| May 04, 2023 Filed May 8, 2023 22:21 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | GrantCommon Shares, $.0011 par value per share | 1,714 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-007585 · form4-05082023_100513.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,085 F1 · price: Subject to the terms of the restricted share agreement, represents restricted shares that will vest on May 4, 2024. Read SEC document |
| October 28, 2022 Filed Nov 1, 2022 22:39 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | PurchaseDepositary Shares, Series G | 2,000 | $17.60 | $35,200.00 |
DisclosureSEC source: 0001415889-22-010947 · form4-11012022_031141.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 F1 · security: Each Depositary Share Represents 1/1,000th interest in a Series G Non-Cumulative Preferred Share. Read SEC document |
| June 07, 2022 Filed Jan 27, 2023 23:31 UTC | BIOGEN INC. BIIB · Entity 1675 | GiftCommon Stock | 150 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-002504 · form5.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,025 Read SEC document |
| May 04, 2022 Filed May 6, 2022 20:04 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | GrantCommon Shares, $.0011 par value per share | 2,642 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-22-002889 · edgar.xml · nonDerivative · entry 2 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,371 F2 · price: Subject to the terms of the restricted share agreement, represents restricted shares that will vest on May 4, 2023 Read SEC document |
| May 04, 2022 Filed May 6, 2022 20:04 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | GrantCommon Shares, $.0011 par value per share | 2,642 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-22-002889 · edgar.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,729 F1 · price: Represents shares granted as part of the director-elected annual retainer for serving as a director of the Issuer. Read SEC document |
| April 29, 2022 Filed May 2, 2022 21:35 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | PurchaseDepositary Shares, Series G | 2,000 | $19.23 | $38,450.00 |
DisclosureSEC source: 0001179110-22-002773 · edgar.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · security: Each Depositary Share Represents 1/1,000th interest in a Series G Non-Cumulative Preferred Share. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 19:24 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | Disposition to issuerDepositary Shares, Series E | 2,000 | $25.00 | $50,000.00 |
DisclosureSEC source: 0001179110-21-009038 · edgar.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Each Depositary Share Represents 1/1,000th interest in a Series E Non-Cumulative Preferred Share. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 21:31 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 775 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-021343 · form4.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,175 Read SEC document |
| June 14, 2021 Filed Jun 15, 2021 22:14 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | SaleDepositary Shares, Series E | 4,000 | $25.24 | $100,971.20 |
DisclosureSEC source: 0001179110-21-006739 · edgar.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · security: Each Depositary Share Represents 1/1,000th interest in a Series E Non-Cumulative Preferred Share. F2 · price: Represents a weighted average sale price; the sale prices range from $25.24 to $25.2435. Upon request, the full information regarding the number of shares sold at each separate price within the range will be provided to the issuer, any security holder of the issuer or the staff of the Securities Exchange Commission. Read SEC document |
| June 04, 2021 Filed Jun 7, 2021 23:02 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 360 | $274.17 | $98,701.20 |
DisclosureSEC source: 0001127602-21-019402 · form4.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,400 F1 · kind: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| May 06, 2021 Filed May 10, 2021 23:28 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | GrantCommon Shares, $.0011 par value per share | 3,143 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-21-005110 · edgar.xml · nonDerivative · entry 2 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,087 F2 · price: Subject to the terms of the restricted share agreement, represents restricted shares that will vest on May 1, 2022. Read SEC document |
| May 06, 2021 Filed May 10, 2021 23:28 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | GrantCommon Shares, $.0011 par value per share | 3,143 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-21-005110 · edgar.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,944 F1 · price: Represents shares granted as part of the director-elected annual retainer for serving as a director of the Issuer. Read SEC document |
| August 03, 2020 Filed Feb 9, 2021 21:15 UTC | BIOGEN INC. BIIB · Entity 1675 | GiftCommon Stock | 125 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004680 · form5.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,760 Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 21:21 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 890 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-019031 · form4.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,885 Read SEC document |
| May 13, 2020 Filed May 15, 2020 18:12 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | PurchaseCommon Shares, $.0011 par value per share | 1,000 | $22.16 | $22,159.40 |
DisclosureSEC source: 0001179110-20-006082 · edgar.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,801 Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:57 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | GrantCommon Shares, $.0011 par value per share | 5,058 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-005631 · edgar.xml · nonDerivative · entry 3 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,801 F3 · price: Subject to the terms of the restricted share agreement, represents restricted shares that will vest on May 1, 2021. Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:57 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | GrantCommon Shares, $.0011 par value per share | 5,058 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-005631 · edgar.xml · nonDerivative · entry 2 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,743 F2 · price: Represents shares granted as part of the director-elected annual retainer for serving as a director of the Issuer. Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:57 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | PurchaseCommon Shares, $.0011 par value per share | 1,000 | $23.72 | $23,717.80 |
DisclosureSEC source: 0001179110-20-005631 · edgar.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,685 F1 · price: Represents a weighted average purchase price; the purchase prices range from $23.715 to $23.719. Upon request, the full purchase information regarding the number of shares purchased at each price increment will be provided to the Commission or to the security holder of the issuer. Read SEC document |
| December 02, 2019 Filed Dec 3, 2019 22:58 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 1,055 | $292.35 | $308,429.25 |
DisclosureSEC source: 0001127602-19-034175 · form4.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,995 F1 · kind: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 21:55 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 1,155 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-022426 · form4.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,050 Read SEC document |
| May 08, 2019 Filed May 9, 2019 21:54 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | GrantCommon Shares, $.0011 par value per share | 2,832 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-19-005791 · edgar.xml · nonDerivative · entry 2 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,685 F2 · price: Subject to the terms of the restricted share agreement, represents restricted shares that will vest on May 1, 2020. Read SEC document |
| May 08, 2019 Filed May 9, 2019 21:54 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | GrantCommon Shares, $.0011 par value per share | 3,726 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-19-005791 · edgar.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,853 F1 · price: Represents shares granted as part of the director-elected annual retainer for serving as a director of the Issuer. Read SEC document |
| February 14, 2019 Filed Feb 15, 2019 21:21 UTC | BIOGEN INC. BIIB · Entity 1675 | GiftCommon Stock | 315 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006317 · form4.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,895 Read SEC document |
| November 28, 2018 Filed Nov 29, 2018 21:52 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | PurchaseCommon Shares, $.0011 par value per share | 500 | $28.24 | $14,118.50 |
DisclosureSEC source: 0001179110-18-013288 · edgar.xml · nonDerivative · entry 2 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,127 Read SEC document |
| November 28, 2018 Filed Nov 29, 2018 21:52 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | PurchaseDepositary Shares, Series F | 500 | $21.86 | $10,932.10 |
DisclosureSEC source: 0001179110-18-013288 · edgar.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · security: Each Depositary Share Represents 1/1,000th interest in a Series F Non-Cumulative Preferred Share. Read SEC document |
| November 05, 2018 Filed Nov 6, 2018 20:00 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | PurchaseDepositary Shares, Series F | 2,500 | $22.45 | $56,124.00 |
DisclosureSEC source: 0001179110-18-012595 · edgar.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 F4 · security: Each Depositary Share Represents 1/1,000th interest in a Series F Non-Cumulative Preferred Share. F2 · price: Represents a weighted average purchase price; the purchase prices range from $22.44 to $22.45. Upon request, the full information regarding the number of shares purchased at each price increment will be provided to the Commission or to a security holder of the issuer. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 21:35 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 880 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-020970 · form4.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,210 Read SEC document |
| May 09, 2018 Filed May 10, 2018 17:42 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | GrantCommon Shares, $.0033 par value per share | 1,196 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-18-006514 · edgar.xml · nonDerivative · entry 2 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,209 F2 · price: Subject to the terms of the restricted share agreement, represents restricted shares that will vest on May 1, 2019. Read SEC document |
| May 09, 2018 Filed May 10, 2018 17:42 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | GrantCommon Shares, $.0033 par value per share | 1,574 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-18-006514 · edgar.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,013 F1 · price: Represents shares granted as part of the director-elected annual retainer for serving as a director of the Issuer. Read SEC document |
| May 03, 2018 Filed May 4, 2018 20:05 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | PurchaseCommon Shares, $.0033 par value per share | 1,000 | $77.38 | $77,380.00 |
DisclosureSEC source: 0001179110-18-006279 · edgar.xml · nonDerivative · entry 2 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,439 Read SEC document |
| May 03, 2018 Filed May 4, 2018 20:05 UTC | ARCH CAPITAL GROUP LTD. ACGL · Entity 3120 | PurchaseCommon Shares, $.0033 par value per share | 2,000 | $79.25 | $158,496.00 |
DisclosureSEC source: 0001179110-18-006279 · edgar.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,439 Read SEC document |
| March 08, 2018 Filed Mar 8, 2018 17:49 UTC | Bioverativ Inc. BIVV · Entity 168487 | Disposition to issuerNon-Qualified Stock Option · Derivative | 26,818 | Not disclosed Strike: $44.51 | Not disclosed |
DisclosureSEC source: 0001127602-18-010675 · form4.xml · derivative · entry 4 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,818 shares Expires not disclosed F4 · shares: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F4 · price: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. Read SEC document |
| March 08, 2018 Filed Mar 8, 2018 17:49 UTC | Bioverativ Inc. BIVV · Entity 168487 | Disposition to issuerNon-Qualified Stock Option · Derivative | 2,980 | Not disclosed Strike: $44.51 | Not disclosed |
DisclosureSEC source: 0001127602-18-010675 · form4.xml · derivative · entry 3 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,980 shares Expires not disclosed F4 · shares: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F4 · price: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.